Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025)
Legend Biotech (LEGN) posted Non-Current Deffered Revenue of $11.3 million for Q4 2025, down 49.95% on a QoQ basis from $22.6 million in Q3 2025, and down 75.91% year-over-year from $46.9 million in Q4 2024.
Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Legend Biotech's Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $11.3 million for Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 75.91% year-over-year to $11.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.3 million (down 75.91% YoY) and the FY2025 annual result came in at $11.3 million, down 75.91% from the prior year.
- Non-Current Deffered Revenue was $11.3 million for Q4 2025 at Legend Biotech, down from $22.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $252.6 million in Q2 2021 and bottomed at -$484000.0 in Q3 2023.
- A 5-year average of $60.1 million and a median of $33.2 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- Peak annual rise in Non-Current Deffered Revenue reached 99081.04% in 2021, while the deepest fall reached 158.77% in 2021.
- Legend Biotech's Non-Current Deffered Revenue stood at -$295000.0 in 2021, then grew by 20.68% to -$234000.0 in 2022, then jumped by 22753.85% to $53.0 million in 2023, then slipped by 11.53% to $46.9 million in 2024, then tumbled by 75.91% to $11.3 million in 2025.
- Business Quant data shows LEGN's Non-Current Deffered Revenue at $11.3 million in Q4 2025, $22.6 million in Q3 2025, and $33.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - | 11.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.30 Mn |
| Sep 30, 2025 | 22.58 Mn |
| Jun 30, 2025 | 33.18 Mn |
| Mar 31, 2025 | 39.54 Mn |
| Dec 31, 2024 | 46.90 Mn |
| Sep 30, 2024 | 63.16 Mn |
| Jun 30, 2024 | 74.85 Mn |
| Mar 31, 2024 | 63.25 Mn |
| Dec 31, 2023 | 53.01 Mn |
| Sep 30, 2023 | -484,000.00 |
| Jun 30, 2023 | -360,000.00 |
| Mar 31, 2023 | -131,000.00 |
| Sep 30, 2022 | -234,000.00 |
| Jun 30, 2022 | -156,000.00 |
| Mar 31, 2022 | 245.85 Mn |
| Dec 31, 2021 | -295,000.00 |
| Sep 30, 2021 | 237.22 Mn |
| Jun 30, 2021 | 252.63 Mn |
| Mar 31, 2021 | 258,666.00 |
| Dec 31, 2020 | -114,000.00 |